Zolbetuximab
Zolbetuximab is a monoclonal antibody that targets claudin 18.2 (CLDN18.2), a protein expressed on certain cancer cells, particularly gastric and gastroesophageal cancers. It works by binding to CLDN18.2-positive cells and triggering immune-mediated cell destruction through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This medication is used in combination with chemotherapy for the treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express CLDN18.2.
Zolbetuximab is a targeted antibody therapy for CLDN18.2-positive gastric and gastroesophageal cancers that works by recruiting the immune system to destroy cancer cells.
Key facts at a glance
- ATC
- L01FX31
- RxNorm
- 2695869
- Generic
- Zolbetuximab
- Class
- atc-l01
- Brands
- Vyloy
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma expressing claudin 18.2 (CLDN18.2) in combination with chemotherapy in adult patients
Zolbetuximab is a claudin 18.2-directed cytolytic antibody that binds to CLDN18.2-positive cells and triggers immune-mediated cell death through two mechanisms: antibody-dependent cellular cytotoxicity (ADCC), where immune cells are recruited to attack the cancer cells, and complement-dependent cytotoxicity (CDC), where the complement system is activated to destroy the target cells.
Administered intravenously; should only be used in patients whose tumors have confirmed CLDN18.2 expression. Common adverse reactions may include nausea, vomiting, decreased appetite, and infusion-related reactions. May interact with other medications; healthcare providers should review full medication history. Pregnancy should be avoided during treatment due to potential harm to the fetus.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy